60 results about "Gastrointestinal tissue" patented technology

The present invention provides devices and methods for attachment of an implanted device, such as an artificial stoma device, a gastrointestinal sleeve device or an attachment cuff, within a patient's digestive tract for treatment of obesity. Special surgical fasteners provide a lasting and durable attachment to the gastrointestinal tissue without causing excessive pressure that could result in tissue erosion and detachment of the implanted device. Fastener delivery devices that facilitate peroral placement and deployment of fasteners and secondary devices are also provided. Also described are implantable devices and attachment means that avoid causing excessive pressure within the tissue by having compliance that is compatible with the gastrointestinal tissues where it is attached.

Apparatus and methods are provided for forming a gastrointestinal tissue fold by engaging tissue at a first tissue contact point, moving the first tissue contact point from a position initially distal to a second tissue contact point to a position proximal of the second contact point to form a tissue fold, and extending an anchor assembly through the tissue fold near the second tissue contact point. Adjustable anchor assemblies, as well as anchor delivery systems, are also provided.

Apparatus and methods are provided for achieving prolonged maintenance of gastrointestinal (“GI”) tissue folds. The apparatus and methods are adapted to form, secure, approximate and promote healing of tissue folds. Such healing may comprise remodeling the tissue folds along region(s) of opposing tissue contact to facilitate prolonged maintenance of the folds. In one variation, the apparatus and methods may be utilized to achieve gastric reduction. The apparatus may be provided as a system of tools.

Apparatus and methods are provided for forming a gastrointestinal tissue fold by engaging tissue at a first tissue contact point and moving the first tissue contact point from a position initially distal to, or in line with, a second tissue contact point to a position proximal of the second contact point, thereby forming the tissue fold, and extending an anchor assembly through the tissue fold from a vicinity of the second tissue contact point. Adjustable anchor assemblies; as well as anchor delivery systems, shape-lockable guides and methods for endoluminally performing medical procedures, such as gastric reduction, treatment of gastroesophageal reflux disease, resection of lesions, and treatment of bleeding sites; are also provided.

Apparatus and methods are provided for forming a gastrointestinal tissue fold by engaging tissue at a first tissue contact point, moving the first tissue contact point from a position initially distal to a second tissue contact point to a position proximal of the second contact point to form a tissue fold, and extending an anchor assembly through the tissue fold near the second tissue contact point.

The invention discloses a gastrointestinal tumor microscopic hyper-spectral image processing method based on a convolutional neural network, comprising the following steps: reducing and de-noising the spectral dimension of an acquired gastrointestinal tissue hyper-spectral training image; constructing a convolutional neural network structure; and inputting obtained hyper-spectral data principal components (namely, a plurality of 2D gray images, which are equivalent to a plurality of feature maps of an input layer) as input images into the constructed convolutional neural network structure using a batch processing method, and by taking a cross entropy function as a loss function and using an error back propagation algorithm, training the parameters in the convolutional neural network and the parameters of a logistic regression layer according to the average loss function in a training batch until the network converges. According to the invention, the dimension of a hyper-spectral image is reduced using a principal component analysis method, enough spectral information and spatial texture information are retained, the complexity of the algorithm is reduced greatly, and the efficiency of the algorithm is improved.

The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

The invention concerns methods and means for facilitating the translocation of molecules through the gastrointestinal tract of mammals. In particular, the invention concerns methods for identifying antibodies, including antibody fragments, capable of translocation from the lumenal side of gastrointestinal tissue into the blood stream or into the lymphatic circulation. The invention further concerns the identification of sequences within or associated with such antibodies facilitating translocation through the gastrointestinal tract. The invention additionally concerns the use of such antibodies and sequences, or other molecules or moieties identified by using such antibodies or sequences, for facilitating oral delivery and absorption of molecules, such as biomolecules (including proteins and nucleic acids), antibodies, peptides, and non-peptide small molecules.

An implantable lead device and method for implanting the lead, wherein the lead device electrically stimulates tissue within a patient's body and more particularly the lead device stimulates gastrointestinal tissue. The implantable lead may be inserted through the tissue with minimal expansion of the penetration tunnel and attached to the tissue being stimulated with minimal efforts or apparatus. The implantable lead has flexible properties thus minimizing the potential for electrode erosion, maximizing tissue compliance, and minimizing the mechanical stress concentration that may result in fatigue failure in the lead.

The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting decreased expression of Indian Hedgehog (Ihh) and/or increased expression of Defensin A5 (DefA5) and/or Defensin A6 (DefA6) in the tissues or cells of the mammal relative to a control.

This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

The invention discloses a blue-light luminous capsule capable of being used for killing helicobacter pylori, which comprises a sealed shell. A control circuit board is arranged in the shell and is successively serially connected with a power source, a switch and an LED bulb emitting blue light, at least one portion in the shell is transparent, and accordingly the light emitted from the LED bulb is transmitted outwards. A blue-light bactericidal principle is adopted to realize the purpose of killing the helicobacter pylori of the gastrointestinal tract of a patient. The blue-light luminous capsule has the advantages of small volume, light weight, independent structure and the like, is applicable to realizing blue-light illumination in severe special environments such as gastrointestinal tracts and the like, can be integrally swallowed by the patient in a medicine taking manner, is used for realizing blue-light illumination for the inner wall of the gastrointestinal tract of the patient, kills the helicobacter pylori, is a pollution-free disposable miniature medical instrument, does not cause any wounds on gastrointestinal tissues and other organs of the patient, is fine in sterilization effect and free of poison and side effects, and excellently resolves problems that traditionally orally administrated medicine is poor in helicobacter pylori killing effect and high in side effects.

The invention discloses a disposable endoscope linear cutting anastomat. The disposable endoscope linear cutting anastomat comprises an anastomat body, a connecting rod, a nail bin body, a second fixing block and illuminating lamps, wherein a fixed handle is fixed to the lower side of the anastomat body and located on the right side of a movable handle, the movable handle is rotationally connected with the anastomat body, a limiting groove is fixed to the left side of the connecting rod, a sleeve is located between disinfection assemblies, a nail bin body is located on the lower side of the nail abutting base, the right side of the interior of the limiting groove is in threaded connection with an auxiliary clamping assembly, and the illuminating lamps are fixed to the left side of the anastomat body. The disposable endoscope linear cutting anastomat can carry out auxiliary disinfection treatment on cut and sutured wounds, can achieve auxiliary clamping and supporting effects on gastrointestinal tissues, can achieve auxiliary lighting and auxiliary photographing effects through a first auxiliary lighting lamp, a second auxiliary lighting lamp and a small anti-fog camera, and has the advantage of ensuring normal use through a power storage assembly when the electric quantity is insufficient.

An in vitro microfluidic gut-on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and gastrointestinal epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal tissue, e.g., Crohn's disease, colitis and other inflammatory gastrointestinal disorders. These multicellular, layered microfluidic gut-on-chip further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal deuodejeum, small intestinal ileium, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.

The invention discloses infant formula milk powder for promoting the development of brain nerves and gastrointestinal tissues of infants and belongs to the technical field of deep processing of dairy products. Each 100g of the infant formula milk powder contains 11-35mg of cholesterol and 10-11 micrograms of epidermal growth factor (EGF). Aiming at the characteristic that infant formula milk powder in the market commonly does not contain cholesterol, proper amount of high-quality cholesterol is added so that fat of the formula milk powder is relatively close to that of breast milk, and the growth development and maturity of organs, especially the development of brains and nerve systems, of infants are promoted. Meanwhile, the EGF, which can promote proliferation and differentiation of cells, is further added into the infant formula milk powder, so that the development and maturity of the tissues and organs of the infants are facilitated.

The invention discloses probiotic fermented Senzhujianzhong oral liquid and a preparation method thereof. The probiotic fermented compound traditional Chinese medicine (the oral liquid) is prepared from ginseng, parched hawthorn fruits, fruits of Chinese magnoliavine, roasted malt and deep-fried atractylodes macrocephala koidz. Experiments prove that the probiotic fermented Senzhujianzhong oral liquid prepared by the invention can significantly increase and improve such indicators as nitric oxide content, nitric oxide synthase content, gastrin and the like in serum and gastrointestinal tissue of rat with symptom of spleen qi deficiency; and the oral liquid is better than Senzhujianzhong oral liquid which is prepared by virtue of an original process in function on treating such symptoms as food stagnation, distention and oppression in stomach duct, indigestion and loss of appetite, insomnia and dreaminess, dizziness and heart palpitations, lassitude of spirit and weakness, and the like.